ClinicalTrials.Veeva
Menu

Find clinical trials for Leukemia in Chicago, IL

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Myeloid Leukemia
Acute Myeloid Leukemia
Lymphoid Leukemia
B-Cell Chronic Lymphocytic Leukemia
Lymphoma
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Myelodysplastic Syndromes

Leukemia trials near Chicago, IL, USA:

Vaccine Therapy for Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL)

This Phase I trial studies the safety and efficacy of vaccine therapy in treating patients with previously untreated chronic lymphocytic leukemia...

Active, not recruiting
Chronic Lymphocytic Leukemia (CLL)
Biological: Oncoquest-CLL vaccine

Phase 1

XEME Biopharma

Chicago, Illinois, United States

inhibitor, in patients with relapsed or refractory acute myeloid leukemia (AML) as part of Phase 1. In Phase 2, assessment of ziftomenib wil...

Enrolling
Acute Leukemia of Ambiguous Lineage
Mixed Phenotype Acute Leukemia
Drug: Ziftomenib

Phase 1, Phase 2

Kura Oncology

Chicago, Illinois, United States and 51 other locations

in children and adolescents with newly diagnosed chronic myeloid leukemia (CML), or in children with Ph+ acute lymphoblastic leukemia...

Active, not recruiting
Leukemia
Drug: Dasatinib

Phase 2

Bristol-Myers Squibb (BMS)
Bristol-Myers Squibb (BMS)

Chicago, Illinois, United States and 173 other locations

Phase 2 dose (RP2D) of revumenib in participants with acute leukemia.In Phase 2, participants will be enrolled in 3 indication-specific expa...

Enrolling
Acute Leukemia of Ambiguous Lineage
Mixed Phenotype Acute Leukemia
Drug: revumenib
Drug: cobicistat

Phase 1, Phase 2

Syndax Pharmaceuticals
Syndax Pharmaceuticals

Chicago, Illinois, United States and 47 other locations

allogeneic hematopoietic stem cell transplant (HCT), versus Conventional Care in patients with Active, Relapsed or Refractory Acute Myeloid Leukemia...

Active, not recruiting
Acute Myelogenous Leukemia
Leukemia, Acute Myeloid
Drug: Conventional Care
Drug: Iomab-B

Phase 3

Actinium Pharmaceuticals
Actinium Pharmaceuticals

Maywood, Illinois, United States and 23 other locations

A Phase 1 first-in-human dose-escalation and dose-expansion study of BMF-500, an oral FLT3 inhibitor, in adult patients with acute leukemia....

Enrolling
Acute Mixed-Phenotype Leukemia
Acute Lymphoblastic Leukemia
Drug: BMF-500

Phase 1

Biomea Fusion

Chicago, Illinois, United States and 22 other locations

Locations recently updated

Acute myeloid leukemia (AML) is the second most common type of leukemia diagnosed in adults and children, but most cases occur in a...

Enrolling
Acute Myeloid Leukemia
Drug: ABBV-787

Phase 1

AbbVie
AbbVie

Chicago, Illinois, United States and 19 other locations

complete outpatient blinatumomab administration for subjects with minimal/measurable residual disease (MRD) of B-precursor Acute Lymphoblastic Leukemia...

Enrolling
B-precursor Acute Lymphoblastic Leukemia
Device: Current Wearable Heatlth Monitoring System (CWHMS)
Drug: Blinatumomab

Phase 4

Amgen
Amgen

Park Ridge, Illinois, United States and 11 other locations

GDX012 is a novel cell therapy developed for the treatment of certain types of cancer, including Acute Myeloid Leukemia (AML). The main aims...

Enrolling
Leukemia
Drug: Chemotherapy Agents
Drug: GDX012

Phase 1, Phase 2

Takeda
Takeda

Chicago, Illinois, United States and 13 other locations

Eligible untreated patients with FLT3 acute myeloid leukemia (AML) between the ages of 18 and 70 will be randomized to receive gilteritinib ...

Active, not recruiting
Acute Myeloid Leukemia
Drug: Gilteritinib
Drug: Daunorubicin

Phase 2

PrECOG

Chicago, Illinois, United States and 43 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems